.jpg)
.png)
All
Esperion has announced that NEXLIZET™ (bempedoic acid and ezetimibe) Is now available in pharmacies in the United States. NEXLIZET™ is an oral, once-daily, fixed-dose combination tablet indicated as an adjunct to diet and maximally tolerated statin for the treatment of adults with... more
The intent of this article is to review the over-the-counter (OTC) products and dietary supplements that have proven effective on cholesterol levels. There is little direct evidence of how these supplements affect cardiovascular outcomes. Additionally, the dosage forms, recommended daily dosage,... more
Hello, I would like the group's input on a patient of mine with hyperalphalipoproteinemia. 9 yo male with, BMI 12 kg/m2 (weight 10th percentile and height 60th percentile), had a routine lipid screen by pcp that showed TC- 223 and HDL > 100. Fasting lipid panel - TC- 184, HDL-C- 108, TG... more
.field.field-name-field-embargo.field-type-datetime.field-label-hidden, .field.field-name-field-rating.field-type-fivestar.field-label-inline.clearfix, .links{ display:none } .body_table li, .head_table li, .body_table p, .head_table p{ line-height: 20px; } .... more
In this LipidSpin edition of the “NLA Impact on the Health Community”, we highlight how the NLA contributes to the understanding of incredibility impactful issues in medicine. The NLA has contributed to many aspects of clinical lipid medicine with scientific statements,... more
Some inherited lipid disorders can be recognized by the deposition of cholesterol and other lipids in lesions on the body termed xanthomas. Lipid deposition can occur in cutaneous and subcutaneous structures, including tendons, with the pattern of deposition characteristic of the underlying genetic... more
Watch PLA leadership discuss the importance of lipid management and the NLA’s role in advancing cardiometabolic care.
It has been an honor to serve as the President of the National Lipid Association (NLA) for the 2018-19 organizational year, and I look forward to the rest of my term through the 2019 Scientific Sessions.
In 1987, to combat the number one killer of American people, cardiovascular disease, the National Cholesterol Education Program (NCEP) released Adult Treatment Panel Guidelines to coincide with the release of the first FDA-approved statin, lovastatin. By 1996, the goal was clear: reduce LDL-C to... more